Original Article
Sittikorn Kulprasertsri, Jutikan Imsub, Sansanee Saengwanitch
Apixaban, one of direct oral anticoagulants
(DOAC) initially approved in 2012, has been shown
to be equivalent or superior to vitamin K antagonist
(VKA) for stroke prevention and has lower rates of
major bleeding in patient with nonvalvular atrial
fibrillation (NVAF)
เมษายน - มิถุนายน 2568